Cited by 165Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug ReactionsCancer, Lipids, and Metabolism

An assessment by the Statin Intolerance Panel: 2014 update

Guyton, John R., Bays, Harold E., Grundy, Scott M., Jacobson, Terry A.·2014·Journal of clinical lipidology

Abstract

This article from the National Lipid Association Statin Intolerance Panel provides a framework for understanding statin intolerance and makes general recommendations for health professionals. For specific guidance on adverse events related to muscle, liver, cognition, and glucose metabolism, one should refer to the other reports of the Statin Safety Task Force for those topics. Although statin adverse effects rarely lead to permanent sequelae, symptomatic intolerance frequently hinders cardiovascular risk reduction by statins. We emphasize here the advisory role of the clinician helping each patient to make personal decisions on statin tolerability. We identify a pressing need for further research on statin intolerance and make suggestions for research design.

Integrity signals

Registry

Crossref · 10.1016/j.jacl.2014.03.002

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The citation lists haven’t been fetched yet

References 46 · Cited by 165

Authors
Guyton, J. R., Bays, H. E., Grundy, S. M., & Jacobson, T. A.
Affiliations
  • Duke University (US)
  • Louisville Metabolic and Atherosclerosis Research Center (US)
  • The University of Texas Southwestern Medical Center (US)
  • Emory University (US)
Corresponding author
Guyton, John R.
Venue
Journal of clinical lipidology
Publisher
Elsevier BV
Published
2014-05
Volume
8
Issue
3
Pages
S72-S81
ISSN
  • 1876-4789 (ISSN-L)
  • 1933-2874
OpenAlex
W1966988082
Cited by
165
References
46
Citations by year
2026: 6 · 2025: 8 · 2024: 7 · 2023: 8 · 2022: 18 · 2021: 4 · 2020: 7 · 2019: 16 · 2018: 19 · 2017: 18 · 2016: 27 · 2015: 18 · 2014: 9
FWCI
23.78
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of clinical lipidology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Sanofi
  • Amgen
  • Genzyme
  • Abbott Laboratories
  • Merck
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
statin intolerance, statin adverse effects, statin tolerability, patient decision-making, cardiovascular risk reduction, statin safety
MeSH terms
Cardiovascular Diseases, Clinical Trials as Topic, Drug Tolerance, Humans, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review